Engagement Inquiries

INSIGHTS & IMPACT

  1. Home
  2. »
  3. INSIGHTS & IMPACT

Clients & Collaborators Testimonials

Dr. Louis is an excellent leader, an innovative scientific collaborator, and a selfless partner. His teams consistently demonstrated high engagement and professionalism.

David Siegel, MD Chief, Myeloma Division

Sherif Louis is a major asset to any biomedical organization. His intelligence, integrity, and leadership have been consistent over nearly two decades.

Hans Knecht, MD Professor Emeritus, McGill University

Sherif helped turn an idea into a respected R&D organization with real commercial potential, spanning IP strategy, KOL engagement, and execution.

Jason Flowerday, MBA Global Healthcare CEO

Sherif combines deep scientific understanding with practical business judgment, which is critical when navigating complex diagnostic IP.

Carmela DeLuca IP Counsel, Smart & Biggar

A disciplined, evidence-driven executive who supports corporate goals with focus and integrity.

Ferenc Somogyvari Former CEO, 3D Signatures

Highlighted Deliverables

Selected Publications

  1. Kumar, S., Rajkumar, S. V., Jevremovic, D., Kyle, R. A., Shifrin, Y., Nguyen, M., Husain, Z., Alikhah, A., Jafari, A., Mai, S., Anderson, K., & Louis, S. (2024). Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma. American Journal of Hematology. https://doi.org/10.1002/ajh.27364

  2. Louis, S., Mai, S., & Knecht, H. (2023). The 3D-Telomere Profiling Assay Identifies High Risk Smoldering Multiple Myeloma Patients with High Precision. Blood, 142 (Supplement 1), 3362. https://doi.org/10.1182/blood-2023-18006

  3. Kumar, S., Rajkumar, V., Jevremovic D., Kyle, R., Mai, S., & Louis, S. (2023). P975: Three-Dimensional Telomere Profiling Predicts Risk Of Relapse In Newly Diagnosed Multiple Myeloma Patients. HemaSphere, 7(S3), e07945f9. https://doi.org/10.1097/01.hs9.0000970804.07945.f9

  4. Kumar, S., S. Vincent Rajkumar, Jevremovic D, Kyle, R. A., Mai, S., & Louis, S. (2023). Three-dimensional telomere profiling to predict risk of progression in smoldering multiple myeloma. Journal of Clinical Oncology, 41(16_suppl), 8056. https://doi.org/10.1200/jco.2023.41.16_suppl.8056

  5. Rangel-Pozzo, A., Yu, I., Lal, S., Asbaghi, Y., Luiza Sisdelli, Tammur P., Tamm, A., Punab, M., Klewes L., Louis, S., Knecht, H., Olujohungbe, A., & Mai, S. (2021). Telomere Architecture Correlates with Aggressiveness in Multiple Myeloma. Cancers, 13(8), 1969. https://doi.org/10.3390/cancers13081969

  6. Louis, S., Rangel-Pozzo, A., Knecht, H., & Mai, S. (2020). Three-Dimensional Telomere Analysis Using Teloview® Technology Identifies Smouldering Myeloma Patients with High Risk of Progression to Full Stage Multiple Myeloma in a Proof-of-Concept Cohort. Blood, 136(Supplement 1), 19–20. https://doi.org/10.1182/blood-2020-140612

  7. Louis, S.F., Vermolen, B. J., Garini, Y., Young, I. T., Guffei, A., Lichtensztejn, Z., Kuttler, F., Chuang, T. C., Moshir, S., Mougey, V., Chuang, A. Y., Kerr, P. D., Fest, T., Boukamp, P., & Mai, S. (2005). c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. Proceedings of the National Academy of Sciences of the United States of America, 102(27), 9613–9618. https://doi.org/10.1073/pnas.0407512102

  8. Guffei, A., Lichtensztejn, Z., Gonçalves Dos Santos Silva, A., Louis, S. F., Caporali, A., & Mai, S. (2007). c-Myc dependent formation of Robertsonian translocation chromosomes in mouse cells. Neoplasia (New York, N.Y.), 9(7), 578–588. https://doi.org/10.1593/neo.07355

➤ For Inquiries or Partnership Opportunities Please Contact

Sherif Louis
Founder & Principle Advisor
sherif.louis@precisionbiotech.net